SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 2,520 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CFO George Cardoza sold 2,520 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $4.85, for a total value of $12,222.00. Following the sale, the chief financial officer owned 295,274 shares in the company, valued at approximately $1,432,078.90. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Tuesday, April 7th, George Cardoza sold 2,413 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.88, for a total value of $11,775.44.
• On Thursday, March 19th, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $3,707.46.

SOPHiA GENETICS Stock Performance

Shares of SOPH traded down $0.01 on Wednesday, reaching $4.89. 64,929 shares of the stock traded hands, compared to its average volume of 188,371. The firm has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The stock’s 50-day moving average price is $4.78 and its 200-day moving average price is $4.68.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after acquiring an additional 31,000 shares in the last quarter. Akre Capital Management LLC grew its position in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter valued at $6,708,000. Finally, Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS during the 3rd quarter valued at $48,000. 31.59% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim increased their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research reissued a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.